TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04051177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Communication with Openness, Passion, and Empowerment ICOPE
Description: The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Curriculum
Description: The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)
Study: NCT01276106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201, 25mg
Description: Capsule, 25mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201, 50mg
Description: Capsule, 50mg BID
Study: NCT02344641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study: NCT05150067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Blended Learning Programme
Description: A blended learning programme with face-to-face training and an online module on handover practice
Study: NCT01276106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201, 75mg
Description: Capsule, 75mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT02066649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Administering carvedilol to patients diagnosed with large varices on endoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Administering carvedilol to patients diagnosed with large varices on endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variceal band ligation
Description: Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variceal band ligation
Description: Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
Study: NCT00656682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietitian Counseling Alone
Description: Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian Plus Community Group Lifestyle
Description: Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
Study: NCT02026011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill, matched to the active study medication in capsule size and color
Study: NCT02805543

Intervention type: DEVICE
Intervention: Color doppler imaging

Intervention type: DEVICE
Intervention: Color doppler imaging
Study: NCT03224039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Intranasal for one dose (experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenous push for one dose (active comparator)
Study: NCT01709526

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Improvement after psychiatric inpatient treatment
Description: Cognition, psychosocial functioning
Study: NCT01730872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
Description: One drop in each eye, four times/day for 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tears Naturale II Ophthalmic Solution
Description: one drop in each eye, four times/ day (QID) for 4 days
Study: NCT03343561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Advice
Description: Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
Study: NCT05150067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control group
Description: The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
Study: NCT00757133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional laparotomy closure
Description: Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy closure with mesh augmentation
Description: Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias
Study: NCT05638308

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FAZA PET/MRI scan
Description: FAZA PET/MRI scan before the standard of care biopsy for case group
Study: NCT03817476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T1)
Description: Intended commercial formulation tablet from batch 1 (iCF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T1)
Description: Intended commercial formulation tablet from batch 1 (iCF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T1)
Description: Intended commercial formulation tablet from batch 1 (iCF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T1)
Description: Intended commercial formulation tablet from batch 1 (iCF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T1)
Description: Intended commercial formulation tablet from batch 1 (iCF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T1)
Description: Intended commercial formulation tablet from batch 1 (iCF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T2)
Description: Intended commercial formulation tablet from batch 2 (iCF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T2)
Description: Intended commercial formulation tablet from batch 2 (iCF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T2)
Description: Intended commercial formulation tablet from batch 2 (iCF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T2)
Description: Intended commercial formulation tablet from batch 2 (iCF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T2)
Description: Intended commercial formulation tablet from batch 2 (iCF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T2)
Description: Intended commercial formulation tablet from batch 2 (iCF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment R)
Description: Trial formulation 2 tablet (TF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment R)
Description: Trial formulation 2 tablet (TF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment R)
Description: Trial formulation 2 tablet (TF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment R)
Description: Trial formulation 2 tablet (TF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment R)
Description: Trial formulation 2 tablet (TF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment R)
Description: Trial formulation 2 tablet (TF2)
Study: NCT00945789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin
Description: Epo dse is 2500 IU/kg subcutaneous daily for 5 days.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: EEG and Brain MRI
Description: EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG and Brain MRI
Description: EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Nitric oxide measurement in the blood
Description: Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
Study: NCT03343561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Advice
Description: Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Advice
Description: Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
Study: NCT00682149

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)
Description: 1 tablet/day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)
Description: 1 tablet/day for 3 months
Study: NCT04197284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback, Myomed 632
Description: Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: device for electrical stimulation, BTL 4000 Smart
Description: Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesitherapy
Description: isometric exercise of the quadriceps muscle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesitherapy
Description: isometric exercise of the quadriceps muscle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesitherapy
Description: isometric exercise of the quadriceps muscle
Study: NCT00334958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rufinamide
Description: For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
Study: NCT00025363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT00945789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nitric oxide measurement in the blood
Description: Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
Study: NCT00767338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: Intrauterine insemination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: Intrauterine insemination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: Intrauterine insemination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: Intrauterine insemination
Study: NCT00945789

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nitric oxide measurement in the blood
Description: Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
Study: NCT04169698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml [Prolia]
Description: full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate 70Mg Tab
Description: Bisphosphonates
Study: NCT01824290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ERA as specific PAH treatment
Description: All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERA as specific PAH treatment
Description: All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
Study: NCT02343770

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample for identifying biomarkers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample for identifying biomarkers
Study: NCT00175929

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Study: NCT00362895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension
Description: One drop in the study eye, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)
Description: One drop in the study eye, single dose
Study: NCT04305977

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WAVE-TW
Description: The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
Study: NCT00613431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS8080
Description: CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
Study: NCT04728568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
Study: NCT04452539

Intervention type: PROCEDURE
Intervention: Paediatric cardiac surgery
Description: All patients undergoing paediatric cardiac surgery
Study: NCT00613431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Some subjects will receive matching placebo instead of CS-8080.
Study: NCT02008994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genomic and Proteomic Profiling
Description: Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
Study: NCT02034643

Intervention type: PROCEDURE
Group type: OTHER
Intervention: balloon pressure adjustment
Description: Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: balloon pressure adjustment
Description: Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
Study: NCT02747758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathodal transcranial direct current stimulation (tDCS)
Description: transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
Study: NCT02962817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video explaining the clinical practice guidelines on low back pain
Study: NCT04134273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLPG Topical Gel 1%
Description: Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin Phosphate topical gel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Study: NCT00855400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminectomy and bone marrow stem cells transplantation
Description: T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cells collection
Description: Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
Study: NCT02316249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
Study: NCT03580122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Aspartate
Description: Asparten